JANX Janux Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why JANX matters now
Janux Therapeutics, Inc. (JANX) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.40 with -2.09% on the session and $1.00B in market capitalization; recent performance reads 1-month +2.97% and YTD +3.04%.
The latest financial table shown here is Q1 2026, with revenue of $3.7M, net income of $-24.4M, and EPS of $-0.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.1%.
The latest indexable market news headline is "Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.00; recent insider activity includes Barrett Ronald W filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.95
P/S
40.12
EV/EBITDA
-7.44
DCF Value
$-3.12
FCF Yield
-9.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.1%
Operating Margin
-726.3%
Net Margin
-529.7%
ROE
-11.8%
ROA
-11.1%
ROIC
-16.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.7M | $-24.4M | $-0.39 |
| Q4 2025 | $7.9M | $-31.9M | $-0.51 |
| FY 2025 | $10.0M | $-113.6M | $-1.83 |
| Q3 2025 | $10.0M | $-24.3M | $-0.39 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$23.40
Target (Median)
$22.00
Target Range
$14.00 - $36.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.52
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.